NABCO Offers New Edition of Its Breast Cancer Resource List

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 12
Volume 4
Issue 12

NEW YORK--The National Alliance of Breast Cancer Organizations (NABCO) has just released the 1995/96 edition of the NABCO Breast Cancer Resource List. This year's 70-page List, supported by an educational grant from Glaxo Wellcome Inc., includes more than 2,000 books, brochures, videos, hotlines, and support groups useful for women and health professionals.

NEW YORK--The National Alliance of Breast Cancer Organizations(NABCO) has just released the 1995/96 edition of the NABCO BreastCancer Resource List. This year's 70-page List, supportedby an educational grant from Glaxo Wellcome Inc., includes morethan 2,000 books, brochures, videos, hotlines, and support groupsuseful for women and health professionals.

The organization said that more than 30,000 copies of the Listwill be distributed to breast cancer survivors and medical offices.

The new NABCO Breast Cancer Resource List may be orderedfrom NABCO, 9 East 37th Street, New York, NY 10016, by enclosinga check for $3.00 and a self-addressed mailing label. Physiciansmay ask for copies with the "Display Copy" legend foruse in waiting rooms.

Articles in this issue
Confusion Abounds Over Breast Cancer Risk Factors
Mislocation of BRCA1 Gene Linked to Nonfamilial Breast Cancer
Regular Aspirin Use May Lower Breast Cancer Risk
Study Probes How Aspirin Decreases Prostaglandin Levels
Scholarships Offered For Palliative Care
Rhône-Poulenc Rorer Acquires Applied Immune Sciences
National Breast Cancer Month Spotlights Awareness Efforts
Long-term Aspirin Use Reduces Colon Cancer Risk, Study Shows
Panel Recommends FDA Approval of First Protease Inhibitor
FDA Improves Drug Approval Times
New Strategies Needed to Boost Clinical Trial Accruals
Attitudes, Knowledge About Cancer Pain Don't Always Jibe
Risk of GI Cancer May Increase After Hodgkin's Disease Treatment
DRGs Underpay for Stem Cell Therapy
NCI Study Shows' Weekly Reader' Conveyed Tobacco Industry Message
Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content
Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.

Inavolisib Combo Receives EU Approval in PIK3CA+ ER+/HER2– Breast Cancer

Russ Conroy
July 24th 2025
Article

Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.

T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer

Roman Fabbricatore
July 18th 2025
Article

The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer

2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer

Anthony Zisa;Marcelo Sleiman Jr;Muriel Statman;Duye Liu;Adina Fleischmann;Kenneth Tercyak
July 16th 2025
Article
3 Intraoperative Radiotherapy: Alive and Well in the Bronx

3 Intraoperative Radiotherapy: Alive and Well in the Bronx

Caroline Oska;Eleni Kohilakis;Jana Fox
July 15th 2025
Article